# The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations

> **NCT03339778** · — · COMPLETED · sponsor: **IMMUNOe Research Centers** · enrollment: 15 (actual)

## Conditions studied

- Primary Immunodeficiency

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03339778
- **Lead sponsor:** IMMUNOe Research Centers
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2016-11
- **Final completion:** 2017-09
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03339778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03339778, "The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03339778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*